<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198659">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504439</url>
  </required_header>
  <id_info>
    <org_study_id>CR2100609</org_study_id>
    <nct_id>NCT00504439</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects.</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled, Dose Ascending, Parallel Group Study to Evaluate the Safety, Tolerability, Steady State Pharmacokinetics and Pharmacodynamics of SB-656933-AAA Following Repeated Doses in Healthy Adult Subjects. The Pharmacokinetic Interaction Between Repeated Doses of SB-656933-AAA and Single Dose of Simvastatin Will Also be Assessed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      To assess safety of SB-656933 following repeat dosing for 14 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, placebo controlled, dose ascending, parallel group study to
      evaluate the safety, tolerability, steady state pharmacokinetics and pharmacodynamics of
      SB-656933-AAA following repeated doses in healthy adult subjects. The pharmacokinetic
      interaction between repeated doses of SB-656933-AAA and single dose of simvastatin will also
      be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety of SB-656933 after repeat doses.</measure>
    <time_frame>after repeat doses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate concentrations of SB-656933 in the body and how long it remains in the body over 14 days of repeat dosing.</measure>
    <time_frame>14 days of repeat dosing.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-656933</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult female, aged 18-65 years.

          -  Female must not be able to have children.

          -  Non-smoking for the last 6 months.

        Exclusion Criteria:

          -  Any serious medical condition.

          -  Hepatitis B or C and/or HIV positive.

          -  Currently on HRT, or other medication except paracetamol.

          -  Body Mass Index &gt;30.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 18, 2017</lastchanged_date>
  <firstreceived_date>July 18, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>SB-656933,</keyword>
  <keyword>COPD,</keyword>
  <keyword>CXCR2,</keyword>
  <keyword>CD11b,</keyword>
  <keyword>repeat dose,</keyword>
  <keyword>safety,</keyword>
  <keyword>tolerability.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
